GT BIOPHARMA, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
GT BIOPHARMA, INC. (GTBP) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of -$169.00 thousand as of 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2018-02-28
- 2017-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$169.00K.
- 2017-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$169.00K.
- 2017-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$169.00K.
- 2016-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$169.00K.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2017-09-30 | -$169.00K 10-Q · filed 2017-11-14 |
| 2017-06-30 | -$169.00K 10-Q · filed 2017-08-11 |
| 2017-03-31 | -$169.00K 10-Q · filed 2017-04-28 |
| 2016-12-31 | -$169.00K 10-Q · filed 2017-11-14 |
| 2016-09-30 | -$169.00K 10-Q/A · filed 2018-02-28 |
| 2015-12-31 | -$169.00K 10-Q/A · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |